Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 14/20 | 0.38 |
| ▸ | CA1 | P00915 | 12/20 | 0.38 |
| ▸ | CA9 | Q16790 | 9/20 | 0.38 |
| ▸ | CA12 | O43570 | 8/20 | 0.38 |
| ▸ | CA4 | P22748 | 8/20 | 0.38 |
| ▸ | CA7 | P43166 | 6/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 6/20 | 0.38 |
| ▸ | CA5A | P35218 | 6/20 | 0.38 |
| ▸ | CA5B | Q9Y2D0 | 6/20 | 0.38 |
| ▸ | CA6 | P23280 | 5/20 | 0.38 |
| ▸ | CA13 | Q8N1Q1 | 3/20 | 0.38 |
| ▸ | CA3 | P07451 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CA11 | O75493 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5036432 | 0.98 | NOS1 (0.46) | NOS1CA2CA1CA9CA12 | |
| SCHEMBL31527670 | 0.96 | NOS1 (0.45) | NOS1CA2CA1CA9CA12 | |
| SCHEMBL3439198 | 0.78 | NOS1 (0.43) | NOS1CA2CA1CA4CA5A | |
| SCHEMBL5039505 | 0.77 | NOS1 (0.41) | NOS1KMT2AMEN1SMN1; SMN2KDM4E | |
| SCHEMBL5323208 | 0.77 | NOS1 (0.41) | NOS1KMT2ATDP1MEN1SMN1; SMN2 | |
| SCHEMBL20679861 | 0.75 | NOS1 (0.40) | NOS1SMN1; SMN2PKMFDPS | |
| SCHEMBL1548616 | 0.72 | CA2 (0.39) | CA2CA1CA9CA12CA4 | |
| SCHEMBL9095017 | 0.72 | CA2 (0.39) | CA2CA1CA9CA12CA4 | |
| SCHEMBL19475256 | 0.72 | CDK2 (0.41) | CA2CA1CA9CA12CA4 | |
| SCHEMBL20679880 | 0.69 | NOS1 (0.35) | NOS1FDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1149091-B1 | 4-(HETEROCYCLYLSULFONAMIDO)-5-METHOXY-6-(2-METHOXYPHENOXY)-2-PHENYL- OR PYRIDYLPYRIMIDINES AS ENDOTHELIN RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2008-03-19 | — | — | EP | disclosed |
| EP-1185525-B1 | 4-HETEROCYCLYLSULFONAMIDYL-6-METHOXY-5-(2-METHOXY-PHENOXY)-2-PYRIDYL-PYRIMIDINE DERIVATIVES, THEIR PREPARATION AND USE AS ENDOTHELIN RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2007-02-07 | — | — | EP | disclosed |
| US-6521631-B2 | N-(6-methoxy-5-(2-methoxy-phenoxy)-2-pyridin-4-yl-pyrimidin-4 -yl)) 5-isopropyl-pyridine-2-sulfonamide; treatment of disorders which are associated with abnormal vascular tone and endothelial dysfunction. | HOFFMANN-LA ROCHE INC. | 2003-02-18 | — | — | US | disclosed |
| US-20020137933-A1 | Heterocyclic sulfonamides | BREU VOLKER (DE) | 2002-09-26 | — | — | US | disclosed |
| US-6417360-B1 | ENDOTHELIN RECEPTOR INHIBITORS; CARDIOVASCULAR DISORDERS, HEART FAILURE | HOFFMANN-LA ROCHE INC. | 2002-07-09 | — | — | US | disclosed |
| EP-1185525-A1 | 4-HETEROCYCLYLSULFONAMIDYL-6-METHOXY-5-(2-METHOXY-PHENOXY)-2-PYRIDYL-PYRIMIDINE DERIVATIVES, THEIR PREPARATION AND USE AS ENDOTHELIN RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-03-13 | — | — | EP | disclosed |
| EP-1149091-A1 | 4-(HETEROCYCLYLSULFONAMIDO)-5-METHOXY-6-(2-METHOXYPHENOXY)-2-PHENYL- OR PYRIDYLPYRIMIDINES AS ENDOTHELIN RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-10-31 | — | — | EP | disclosed |
| US-6242601-B1 | ENDOTHELIN RECEPTORS INHIBITORS SUCH AS 4-(4-METHOXY-5-(2-METHOXY-PHENOXY)-6-(5-METHYL-PYRIDINE-2-SULF ONYLAMINO)-PYRIMIDIN-2-YL)-PYRIDINE-2-CARBOXYLIC ACID USED TO TREAT CARDIOVASCULAR SYSTEM DISORDERS | HOFFMAN-LA ROCHE INC. | 2001-06-05 | — | — | US | disclosed |
| WO-2000052007-A1 | 4-HETEROCYCLYSULFONAMIDYL-6-METHOXY-5-(2-METHOXY-PHENOXY)-2-PYRIDYL-PYRIMIDINE DERIVATIVES, THEIR PREPARATION AND USE AS ENDOTHELIN RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2000-09-08 | — | — | WO | disclosed |
| WO-2000042035-A1 | 4-(HETEROCYCLYLSULFONAMIDO) -5-METHOXY-6- (2-METHOXYPHENOXY) -2-PHENYL- OR PYRIDYLPYRIMIDINES AS ENDOTHELIN RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2000-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137933-A1 | Heterocyclic sulfonamides | ECE1, EDNRA, EDNRB | NOS1 16/4885CA2 539/4885CA1 2330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.